On April 26, 2023 Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable immune response, reported that it will present dose expansion data from the ongoing Phase 1/1b clinical trial of its lead investigational candidate, BCA101, in combination with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma (Press release, Bicara Therapeutics, APR 26, 2023, View Source;utm_medium=rss&utm_campaign=bicara-therapeutics-announces-oral-presentation-of-head-and-neck-cancer-dose-expansion-data-from-phase-1-1b-study-of-bca101-at-upcoming-2023-asco-annual-meeting [SID1234630513]). BCA101 is a first in class dual-action bifunctional antibody designed to inhibit EGFR and disable TGF-β directly at the tumor site. These data will be presented in an oral presentation at the upcoming 2023 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting being held from June 2-6, 2023 in Chicago, IL.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the oral presentations are as follows:
Title: Dose expansion results of the bifunctional EGFR/TGF-β inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma.
Presenter: Glenn J. Hanna, M.D.
Abstract Number: 6005
Session Type/Title: Oral Abstract Session – Head and Neck Cancer
Date/Time: June 5, 2023 from 8:00-11:00 a.m. CT
Location: McCormick Place Convention Center
This presentation described here will be made available on the Bicara website following the conference.